These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26293616)

  • 1. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
    Hoeben E; De Winter W; Neyens M; Devineni D; Vermeulen A; Dunne A
    Clin Pharmacokinet; 2016 Feb; 55(2):209-23. PubMed ID: 26293616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Stieltjes H; Ariyawansa J; Di Prospero NA; Rothenberg P
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):279-86. PubMed ID: 27136908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS.
    Dong ST; Niu HM; Wu Y; Jiang JL; Li Y; Jiang KY; Wang X; Zhang MF; Han MF; Meng SN
    Molecules; 2018 May; 23(5):. PubMed ID: 29783787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.
    Riggs MM; Staab A; Seman L; MacGregor TR; Bergsma TT; Gastonguay MR; Macha S
    J Clin Pharmacol; 2013 Oct; 53(10):1028-38. PubMed ID: 23940010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
    Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
    Naik H; Czerniak R; Vakilynejad M
    Br J Clin Pharmacol; 2016 Apr; 81(4):700-12. PubMed ID: 26617339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
    Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
    Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D
    Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Polidori D; Argenti D; Di Prospero NA
    Pediatr Diabetes; 2018 Jun; 19(4):649-655. PubMed ID: 29271103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
    Francke S; Mamidi RN; Solanki B; Scheers E; Jadwin A; Favis R; Devineni D
    J Clin Pharmacol; 2015 Sep; 55(9):1061-72. PubMed ID: 25827774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of gliclazide in normal and diabetic rabbits.
    Shaik M; Shaik S; Kilari EK
    Biopharm Drug Dispos; 2018 May; 39(5):265-274. PubMed ID: 29679474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The method of averaging applied to pharmacokinetic/pharmacodynamic indirect response models.
    Dunne A; de Winter W; Hsu CH; Mariam S; Neyens M; Pinheiro J; Woot de Trixhe X
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):417-26. PubMed ID: 26142076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.